Clinical trials: SARS-COV2 Virus
COVID-19
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators.
- Trial name
- NCT05541510
- Testing
- AD17002 + Formulation buffer
- Where
- 3 sites in Indonesia
- Volunteers
- 180 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Covid-19
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
- Trial name
- NCT04522817
- Testing
- CLBS119
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
COVID-19
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19.
- Trial name
- BOSS-002 (NCT05785390)
- Testing
- NP-101
- Where
- 4 sites in United States
- Volunteers
- 170 people
- Sponsor
- Novatek Pharmaceuticals
COVID-19, SARS CoV 2 Infection
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
This is a Multi-Part, Phase 3, randomized, observer-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike…
- Trial name
- COVID-19 (NCT05372588)
- Testing
- NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515
- Where
- 19 sites in Australia
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19
The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care
This is an adaptive, randomized, double-blinded, placebo-controlled, Phase II/III study conducted to evaluate the effect of SCTA01 on participant survival and clinical efficacy in participants with severe COVID-19 admitted to…
- Trial name
- NCT04683328
- Testing
- SCTA01
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.
COVID-19, SAR
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a major threat to human health.
- Trial name
- NCT04777981
- Testing
- CBDRA60 supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anewsha Therapeutics Inc.
COVID-19 (Coronavirus Disease 2019)
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.
- Trial name
- NCT07072793
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 131,005 people
- Sponsor
- Pfizer
COVID 19
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent…
- Trial name
- NCT06698549
- Testing
- ALG-097558
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345…
- Conditions
- SARS-CoV-2, Influenza, RSV
- Trial name
- NCT05585632
- Testing
- mRNA-1010, mRNA-1345, mRNA-1273.214
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 Acute Respiratory Disease
A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19
The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.
- Trial name
- NCT05042193
- Testing
- SARS-CoV-2
- Where
- United States
- Volunteers
- 1,883 people, healthy volunteers welcome
- Sponsor
- Everly Health
SARS-CoV-2
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
- Trial name
- NCT04447404
- Testing
- DUR-928
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Durect
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
A total of 1200 people aged 18 years and older who have completed two or three-dose inactivated COVID-19 vaccine for 6-18 months will be recruited in this study.
- Trial name
- NCT05664932
- Testing
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
This study is an adaptive Phase III randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed with COVID-19.
- Trial name
- NCT05009732
- Testing
- GT0918, Standard of care
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 139 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
COVID-19
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19.
- Trial name
- COMMUNITY (NCT04590586)
- Testing
- Standard of care, Apremilast, Lanadelumab
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 515 people
- Sponsor
- Amgen
Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder)
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.
- Conditions
- Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
- Trial name
- NCT04705831
- Testing
- Ruconest
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- IMMUNOe Research Centers
Covid19
Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).
An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic strain on the immune response in participants positive for SARS-CoV-2 infection.
- Trial name
- PROVID (NCT04937556)
- Testing
- Probiotic: Lactobacillus salivarius + Vit D + Zinc
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- ProbiSearch SL
Covid19, SARS-CoV-2
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19…
- Trial name
- NCT04652102
- Testing
- CVnCoV, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
- Where
- 46 sites in Argentina, Belgium and 8 more
- Volunteers
- 39,680 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19 Pandemic
Intranasal INNA-051 for Prevention of COVID-19 in Adults
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection.
- Trial name
- NCT05118763
- Testing
- INNA-051
- Volunteers
- healthy volunteers welcome
- Sponsor
- ENA Respiratory Pty Ltd
COVID-19
Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)
In late December 2019, a new coronavirus strain emerged in China causing coronavirus disease 2019 (COVID-19). Since then, COVID-19 has become a global pandemic outbreak being declared a "public health emergency of international…
- Trial name
- CONDITION (NCT04389658)
- Where
- Spain
- Volunteers
- 1,526 people, healthy volunteers welcome
- Sponsor
- Igenomix